跳至主要内容
临床试验/NCT03013868
NCT03013868Unknown不适用

CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System

MiCareo Taiwan Co., Ltd.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2016年10月最近更新:
适应症

试验速览

阶段
不适用
入组人数
200
试验地点
1
主要终点
Disease Free Survival

研究概览

简要总结

Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan. The cause of CRC mortality is due mainly to the occurrence of distant metastasis. Several reports suggested that circulating tumor cells (CTCs) highly associated with metastasis suggesting that targeting CTCs may offer an unprecedented opportunity to prevent the development of metastasis. Early detection and characterization of CTCs is therefore important as a potential strategy to monitor the progression of CRC. The current proposal is focused on detecting CTCs from peripheral blood of CRC patients using Miselect R system. We will monitor the amount of CTCs and correlate with CRC progression and prognosis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Over 20 and less than 90 years of age.
  • Colorectal cancer stage II/III patients who will undergo surgical resection.
  • Subject having agreed to participate in the study and follow the study procedures by providing written informed consent prior entering the study.

排除标准

  • Have other cancer history.
  • Subject being identified with any blood borne infectious disease

结局指标

主要结局

Disease Free Survival

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

CTCs and Novel Target Bio-marker Analysis for... | 临床试验